GlassScriptPhysician profile
Trisha Louise Taron
NPI 1710355060
$5,479.77
in general payments reported to CMS, 2019-2025
25 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,185 · 2022: $1,026 · 2023: $1,073 · 2024: $1,112 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,268.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,891.81 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $556.27 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $338.02 | 2021-2025 | |
| Celgene Corporation | $276.80 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $153.75 | 2021 | |
| Janssen Biotech, INC. | $143.68 | 2021-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $120.72 | 2021 | |
| Novo Nordisk INC | $107.66 | 2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.41 | 2021-2025 | Trulance |
| E.R. Squibb & Sons, L.L.C. | $97.76 | 2023 | Zeposia |
| Ardelyx, INC. | $91.02 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $77.45 | 2021-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $71.07 | 2023-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $70.20 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $68.24 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $59.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $55.53 | 2024-2025 | |
| Qol Medical, LLC | $52.64 | 2022-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $42.12 | 2022-2023 | Dificid |
| Ipsen Biopharmaceuticals, INC | $25.16 | 2025 | Iqirvo |
| Pfizer INC. | $21.46 | 2024 | |
| Redhill Biopharma INC. | $15.18 | 2021 | |
| Lilly USA, LLC | $14.31 | 2025 | Mounjaro, Zepbound |
| Mallinckrodt Hospital Products INC. | $13.35 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Taron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.